Next Article in Journal
Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis
Next Article in Special Issue
Endothelial Dysfunction: A Contributor to Adverse Cardiovascular Remodeling and Heart Failure Development in Type 2 Diabetes beyond Accelerated Atherogenesis
Previous Article in Journal
Sleep Quality and Sleep Disturbance Perception in Dual Disorder Patients
Previous Article in Special Issue
Activated L-Arginine/Nitric Oxide Pathway in Pediatric Cystic Fibrosis and Its Association with Pancreatic Insufficiency, Liver Involvement and Nourishment: An Overview and New Results
Open AccessArticle

Association of Lower Plasma Homoarginine Concentrations with Greater Risk of All-Cause Mortality in the Community: The Framingham Offspring Study

1
Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, and DZHK Partner Site Hamburg/Kiel/Lübeck, 20246 Hamburg, Germany
2
Department of Epidemiology, Boston University School of Public Health, Boston, MA 02118, USA
3
Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, MA 02118, USA
4
Framingham Heart Study, Framingham, MA 01702, USA
5
Computing and Data Sciences Institute, Boston University, Boston, MA 02215, USA
6
Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(6), 2016; https://doi.org/10.3390/jcm9062016
Received: 14 May 2020 / Revised: 3 June 2020 / Accepted: 24 June 2020 / Published: 26 June 2020
(This article belongs to the Special Issue Atherosclerosis: Endothelial Dysfunction and Beyond)
Lower circulating homoarginine concentrations have been associated with morbidity and mortality in patients with established cardiovascular disease (CVD). We assayed plasma homoarginine concentrations in 3331 Framingham Offspring Study participants attending examination cycle six (mean age 58.6 years, 53% women). We evaluated correlates of plasma homoarginine and related homoarginine to incident CVD and death. We also classified participants as having higher (upper quartile) versus lower (lower three quartiles) homoarginine and previously assayed asymmetric dimethylarginine (ADMA) concentrations, and created cross-classification groups. We observed 630 incident CVD events and 940 deaths during a median follow-up of 18 years. In multivariable regression analysis, homoarginine was associated positively with male sex, body mass index, anti-hypertensive medication use and systolic blood pressure, but inversely with age and smoking. Higher homoarginine levels were associated with a lower mortality risk (hazard ratio (HR) per SD increment, 0.83, 95% CI: 0.74–0.93) adjusting for standard CVD risk factors, and ADMA. Among the cross-classification groups, participants with higher homoarginine and lower ADMA had a lower mortality risk (HR, 0.81, 95% CI: 0.67–0.98) compared to those with low levels of both. Further studies are needed to dissect the mechanisms of the association of homoarginine and mortality over decades in the community. View Full-Text
Keywords: cardiovascular disease; homoarginine; nitric oxide; risk factors cardiovascular disease; homoarginine; nitric oxide; risk factors
Show Figures

Figure 1

MDPI and ACS Style

Schwedhelm, E.; Song, R.J.; Vasan, R.S.; van den Heuvel, E.R.; Hannemann, J.; Xanthakis, V.; Böger, R. Association of Lower Plasma Homoarginine Concentrations with Greater Risk of All-Cause Mortality in the Community: The Framingham Offspring Study. J. Clin. Med. 2020, 9, 2016.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop